Iovance Biotherapeutics, Inc. (IOVA)
| Market Cap | 7.48B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -254.75M |
| Shares Out | 146.49M |
| EPS (ttm) | -1.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $50.93 |
| Previous Close | $51.06 |
| Change ($) | -0.13 |
| Change (%) | -0.25% |
| Day's Open | 52.00 |
| Day's Range | 50.43 - 53.01 |
| Day's Volume | 1,017,529 |
| 52-Week Range | 19.54 - 53.01 |
SAN CARLOS, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...
Iovance is ramping up tumor-infiltrating lymphocytes as an ingenious way to eradicate cancers. As such, I believe it'll continue to deliver stellar data. Riding robust data, LPN-145 and lifile...
SAN CARLOS, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...
SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?
SAN CARLOS, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...
Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.
44.4% Overall Response Rate (ORR) and Median Duration of Response (DOR) Not Reached at 8.6 Months of Study Follow Up
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q3 2020 Results - Earnings Call Transcript
SAN CARLOS, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, wil...
In this article we are going to use hedge fund sentiment as a tool and determine whether Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a good investment right now. We like to analyze hedge fu...
SAN CARLOS, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...
Iovance Biotherapeutics, in an attempt to secure FDA-approval for their biologic, lifileucel, in advanced melanoma, was set back as the FDA requires some more information. This can't come to m...
Smaller biotechs would make nice additions to pharma companies in similar areas of therapy
SAN CARLOS, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...
NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors...
Iovance (IOVA) delays its application to the FDA for a tumor-infiltrating lymphocyte (TIL) therapy, lifileucel, for the treatment of metastaic melanoma until later in 2021.
Shares of Iovance Biotherapeutics Inc. iova were down 20.0% in premarket trading on Tuesday, the day after the biotechnology company said it plans to now submit an application to the Food and ...
SAN CARLOS, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...
SAN CARLOS, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, tod...
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?
Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.
SAN CARLOS, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, t...
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q2 2020 Results - Earnings Call Transcript
Enrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer Study Enrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer Study
SAN CARLOS, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, w...
The pandemic has put the health care industry under a global spotlight.
After rumors swirled about a potential acquisition, it now appears the biopharma is transitioning to commercial operations as a standalone company.
Adding One More Dimension In Solid Tumor Therapy - Iovance Biotherapeutics
SAN CARLOS, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, t...
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?
Offering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 2.5 Million Shares of Common Stock Offering Includes Exercise in Full of the Underwriters’ Option to Pu...
Iovance Biotherapeutics (IOVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up
SAN CARLOS, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based ca...
The biotech company is looking to raise up to $575 million ahead of its transition to commercial-stage operations.
Iovance Biotherapeutics (NASDA:IOVA) shares are trading lower on Thursday, after the company announced a $500 million proposed public offering of common stock.
Iovance unveiled promising test results for a cancer treatment, but IOVA stock tumbled Thursday on a subsequent public offering. Proceeds will be used, in part, to launch the drug.
SAN CARLOS, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based c...
Cohort 4 Early Data Shows 32.4% ORR by Investigator Assessment at 5.3 Months of Median Study Follow up
Median Duration of Response Not Reached at 17.0 Months of Median Study Follow Up in C-144-01 Study
Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.
Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q1 2020 Results - Earnings Call Transcript
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) might be even more attractive to rumored suitors after the San Francisco-area company’s cancer-fighting treatment showed promise in early testing.
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
The worst is yet to come for the stock market, but these biopharma companies have promising potential.
Iovance Biotheraputics: Still Well-Poised To Treat Solid Tumors
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
About IOVA
Iovance Biotherapeutics, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcin... [Read more...]
| Industry Biotechnology | Founded 2007 |
| CEO Maria Fardis | Employees 148 |
| Stock Exchange NASDAQ | Ticker Symbol IOVA |
Analyst Forecasts
According to 12 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price forecast is 51.45, which is an increase of 1.02% from the latest price.